Key takeaway: Innova Captab Limited's investor presentation, dated August 11, 2026, provided an overview of the company's financial performance for the quarter ended June 30, 2026. Management reported a revenue increase of 34% year-on-year, reaching ₹470.9 crore, with EBITDA growing by 33% to ₹75.1 crore. The presentation highlighted the company's diversified business model, with CDMO Services and Products contributing approximately 70% of total revenue. Profit after tax also saw a significant rise of 42%, amounting to ₹44.1 crore. The document detailed the company's strategic growth initiatives, including the ramp-up of its Jammu facility and ongoing expansion of manufacturing capabilities. Management emphasized a commitment to operational excellence and maintaining strong customer relationships. The presentation concluded with a focus on long-term value creation for stakeholders.

Key takeaway: Innova Captab Limited reported its highest annual performance for FY '26, with revenue reaching INR 1,630 crores, a 31% year-on-year increase. Q4 revenue was INR 448 crores, reflecting a 42% growth compared to the same quarter last year. The growth was attributed to strong performance in both the CDMO and Branded Generics segments. The CDMO business generated INR 1,133 crores, up 24%, while Branded Generics saw a 51% increase, reaching INR 497 crores. Management highlighted the successful ramp-up of the Jammu facility and noted significant regulatory approvals that would enhance market entry. EBITDA for FY '26 was INR 250.3 crores, with a profit after tax of INR 140.9 crores, marking a 10% increase. Management expressed confidence in achieving over 20% revenue growth in the future, supported by operational efficiencies and capacity expansion plans.

Key takeaway: Innova Captab Limited's investor presentation detailed the company's financial results for the quarter and fiscal year ending March 31, 2026. Management reported a year-over-year revenue growth of 42% in Q4 FY26 and 31% for the full fiscal year, driven by strong performance in both CDMO and branded generics segments. The presentation highlighted an EBITDA of ₹250.3 crore for FY26, reflecting a 26% increase, and a profit after tax (PAT) of ₹140.9 crore, up 10% year-over-year. The company emphasized its operational excellence, supported by state-of-the-art manufacturing facilities and key certifications received during the year. Management noted the successful ramp-up of the Jammu facility and the expansion of its product portfolio, which contributed to increased customer engagement. The document also outlined the company's strategic growth initiatives and commitment to delivering long-term value to stakeholders.